Iranian Journal of Pathology

Investigation of PD-L1 Expression in Various Non-Hodgkin's B-cell Lymphomas

Document Type : Original Research

Authors

Pardis Nematollahi 1
Shiva Radfar 2

1 Department of Pathology, School of Medicine, Cancer Prevention Research Center, Seyyed Al-Shohada Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

https://doi.org/10.30699/ijp.2025.2051609.3406
Abstract
Background & Objective: Programmed death ligand-1 (PD-L1) plays a critical role in tumor immune evasion, particularly in Non-Hodgkin’s B-cell lymphomas (NHL). This study aimed to evaluate PD-L1 expression across various NHL immunophenotypes and assess its correlation with clinical and demographic parameters.
Methods: In this cross-sectional, descriptive-analytical study, 71 formalin-fixed, paraffin-embedded tissue blocks diagnosed with Non-Hodgkin’s B-cell lymphoma were retrieved from the pathology archives of Alzahra Hospital and Seyed-al Shohada (Omid) Hospital in Isfahan (2019–2020). PD-L1 expression was assessed immunohistochemically using tumor proportion score (TPS), combined proportion score (CPS), and immune cell (IC) score. Statistical analysis was performed using the Mann-Whitney U and Kruskal-Wallis tests, with p < 0.05 considered statistically significant.
Results: Among the 71 patients, 67.6% were male, with a mean age of 52.61 ± 18.43 years. Diffuse large B-cell lymphoma (DLBCL) was the most common subtype, accounting for 52.1% of cases. PD-L1 expression was significantly higher in females (TPS: 18.13 ± 9.73; CPS: 28.22 ± 13.31) compared to males (TPS: 4.42 ± 3.56; CPS: 12.08 ± 10.14) (p = 0.040, p = 0.022). No significant differences in PD-L1 expression were observed across age groups. DLBCL demonstrated significantly higher IC and CPS values compared to other subtypes (p < 0.05), while plasmacytoma and Burkitt lymphoma exhibited the lowest scores (e.g., immune score: 1.11 ± 0.11 for plasmacytoma). No statistically significant differences in TPS were noted among the different immunophenotypes (p = 0.119).
Conclusion: Elevated PD-L1 expression, particularly in immune cell scores, suggests potential utility in PD-1/PD-L1–targeted therapies for NHL. However, the prognostic significance of PD-L1 remains inconclusive, highlighting the need for further investigation into its role as a predictive biomarker in the clinical management of Non-Hodgkin’s B-cell lymphomas.

Keywords

PD-L1
Non-Hodgkin’s lymphoma
immunophenotype
immunohistochemistry
DLBCL
cancer immunotherapy

Subjects

  1. Pasqualucci L. Molecular pathogenesis of germinal center‐derived B cell lymphomas. Immunol Rev. 2019;288(1):240-61. [DOI:10.1111/imr.12745] [PMID]
  2. Ok CY, Young KH. Targeting the programmed death-1 pathway in lymphoid neoplasms. Cancer Treat Rev. 2017;54:99-109. [DOI:10.1016/j.ctrv.2017.01.009] [PMID] [PMCID]
  3. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4(5):336-47. [DOI:10.1038/nri1349] [PMID]
  4. Ishida M, Iwai Y, Tanaka Y, Okazaki T, Freeman GJ, Minato N, et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett. 2002;84(1):57-62. [DOI:10.1016/S0165-2478(02)00142-6] [PMID]
  5. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800. [DOI:10.1038/nm730] [PMID]
  6. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261-8. [DOI:10.1038/85330] [PMID]
  7. Zhang Y, Chung Y, Bishop C, Daugherty B, Chute H, Holst P, et al. Regulation of T cell activation and tolerance by PD-L2. Proc Natl Acad Sci USA. 2006; 103(31):11695-700. [DOI:10.1073/pnas.0601347103] [PMID] [PMCID]
  8. Tsao MS, Le Teuff G, Shepherd FA, Landais C, Hainaut P, Filipits M, et al. PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer. Ann Oncol. 2017;28(4):882-9. [DOI:10.1093/annonc/mdx003] [PMID] [PMCID]
  9. Chen Y, Wang Q, Shi B, Xu P, Hu Z, Bai L, et al. Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. Cytokine. 2011;56(2):231-8. [DOI:10.1016/j.cyto.2011.06.004] [PMID]
  10. Zappasodi R, de Braud F, Di Nicola M. Lymphoma immunotherapy: current status. Front Immunol. 2015;6:448. [DOI:10.3389/fimmu.2015.00448] [PMID] [PMCID]
  11. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450-61. [DOI:10.1016/j.ccell.2015.03.001] [PMID] [PMCID]
  12. Xerri L, Chetaille B, Seriari N, Attias C, Guillaume Y, Arnoulet C, et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol. 2008;39(7):1050-8. [DOI:10.1016/j.humpath.2007.11.012] [PMID]
  13. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MGM, Xu ML, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013; 19(13):3462-73. [DOI:10.1158/1078-0432.CCR-13-0855] [PMID] [PMCID]
  14. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17(13):4232-44. [DOI:10.1158/1078-0432.CCR-10-2660] [PMID]
  15. Muenst S, Hoeller S, Dirnhofer S, Tzankov A. Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol. 2009;40(12):1715-22. [DOI:10.1016/j.humpath.2009.03.025] [PMID]
  16. Muenst S, Hoeller S, Willi N, Dirnhofer S, Tzankov A. Diagnostic and prognostic utility of PD-1 in B cell lymphomas. Dis Markers. 2010;29(1):47-53. [DOI:10.1155/2010/404069] [PMID] [PMCID]
  17. Jiang D, Song Q, Wang H, Huang J, Wang H, Hou J, et al. Independent prognostic role of PD-L1 expression in patients with esophageal squamous cell carcinoma. Oncotarget. 2017;8(5):8315. [DOI:10.18632/oncotarget.14174] [PMID] [PMCID]
  18. Xia H, Shen J, Hu F, Chen S, Huang H, Xu Y, et al. PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients. Clin Chim Acta. 2017;469:191-4. [DOI:10.1016/j.cca.2017.02.005] [PMID]
  19. Chen S, Wang RX, Liu Y, Yang WT, Shao ZM. PD‐L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. Int J Cancer. 2017;140(6): 1384-95. [DOI:10.1002/ijc.30552] [PMID]
  20. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci Transl Med. 2013;5(200):200ra116. [DOI:10.1126/scitranslmed.3006504] [PMID] [PMCID]
  21. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37. [DOI:10.1126/scitranslmed.3003689] [PMID] [PMCID]
  22. Mahoney KM, Sun H, Liao X, Hua P, Callea M, Greenfield EA, et al. PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells. Cancer Immunol Res. 2015;3(12):1308-15. [DOI:10.1158/2326-6066.CIR-15-0116] [PMID] [PMCID]
  23. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-35. [DOI:10.1056/NEJMoa1504627] [PMID] [PMCID]
  24. Georgiou K, Chen L, Berglund M, Ren W, De Miranda NFCC, Lisboa S, et al. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood. 2016;127(24):3026-34. [DOI:10.1182/blood-2015-12-686550] [PMID]
  25. Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: Implications for targeted therapy. Clin Cancer Res. 2012;18:1611-1618. [DOI:10.1158/1078-0432.CCR-11-1942] [PMID] [PMCID]
  26. Zhang W, Bai J-F, Zuo M-X, Cao X-X, Chen M, Zhang Y, et al. PD-1 expression on the surface of peripheral blood CD4+ T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma. Cancer Med. 2016;11:3077-3084. [DOI:10.1002/cam4.874] [PMID] [PMCID]
  27. Zodelava M, Datikashvili-David I. Prognostic significance of apoptosis-related CD95 antigen expression in patients with non-Hodgkin's lymphoma. Georgian Med. 2005;120:37-39. [PMID]
  28. Ibrahim EM, Refat S, El-Ashwah S, Fahmi MW, Ibrahiem AT. Programmed death ligand 1 expression in diffuse large B cell lymphoma: correlation with clinicopathological prognostic factors. J Egypt Natl Canc Inst. 2023;35(1):12. [DOI:10.1186/s43046-023-00171-6] [PMID]
  29. Zhao S, Zhang M, Zhang Y, Meng H, Wang Y, Liu Y, et al. The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis. Cancer Biol Med. 2018;15(3):290. [DOI:10.20892/j.issn.2095-3941.2018.0047] [PMID] [PMCID]
  30. Zeng Q, Liu Z, Liu T. Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis. BMC Cancer. 2020;20(1):1-10. [DOI:10.1186/s12885-020-6550-z] [PMID] [PMCID]
  31. Qiu L, Zheng H, Zhao X. The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis. BMC Cancer. 2019;19(1):1-12. [DOI:10.1186/s12885-019-5466-y] [PMID] [PMCID]
  32. Yoon DH, et al. PD-L1 expression as a prognostic factor in peripheral T-cell lymphoma. Haematologica. 2018;103(2):275-282.
  33. Zinzani PL, et al. Tumor-infiltrating lymphocytes as a prognostic factor in lymphoma: A new perspective on immune checkpoint inhibitors. Br J Haematol. 2019;184(2):169-172. [PMID] [PMCID] [doi: 10.1080/14737159.2024.2312102]
  34. Schuster SJ, et al. Monoclonal antibodies and CAR T-cell therapy: A synergistic approach for treating B-cell malignancies. Blood. 2018;132(20):2187-2193.
  35. Klapper W, et al. Standardization of PD-L1 status testing in lymphomas: Recommendations for clinical practice. J Mol Diagn. 2020;22(4):427-446.
  36. Alimonti P, Gonzalez Castro LN. The current landscape of immune checkpoint inhibitor immunotherapy for primary and metastatic brain tumors. Antibodies. 2023;12(2):27. [DOI:10.3390/antib12020027] [PMID] [PMCID]
Iranian Journal of Pathology
Volume 20, Issue 4
Summer 2025
Pages 471-477

  • Receive Date 24 January 2025
  • Revise Date 17 March 2025
  • Accept Date 26 July 2025

Home

Guide for Authors

Submit Manuscript

Contact Us